Tumour survival, growth, and proliferation demand complex and broad biological capabilities, including proliferative signalling, evasion of growth suppressors, promotion of local blood vess
In this new episode of the mini pharmaphorum podcast, web editor Nicole Raleigh spoke with Steven Powell, CEO of Ribonexus, a new company put together to develop and ultimately commercialis
Sage Therapeutics has suffered another disappointment after deciding that it will have to drop the Parkinson’s programme for key pipeline drug dalzanemdor after it showed
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.